



MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

UPDATE ON WINDING UP OF AN INDIRECT MAJORITY-OWNED SUBSIDIARY

- **FIRST AND FINAL DIVIDEND VIA DISTRIBUTION *IN SPECIE* OF SHARES IN RMKH GLOVE PTE. LTD. HELD BY RESILIENT MEDICAL PTE. LTD. TO MEDTECS INTERNATIONAL CORPORATION LIMITED**

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025, 24 January 2025, 27 February 2025, 27 March 2025 and 25 April 2025 (the "**Announcements**") in relation to the winding up of Resilient Medical Pte. Ltd. ("**Resilient Medical**"). Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. DECLARATION OF DIVIDEND IN SPECIE TO THE COMPANY

As disclosed in the Announcements, the Liquidator had commissioned the valuers to conduct a valuation of the property, plant, equipment and inventories of RMKH Glove (Cambodia) Co., Ltd ("**RMKH Cambodia**", being a wholly-owned subsidiary of RMKH Glove Pte. Ltd. ("**RMKH SG**") which in turn is a wholly-owned subsidiary of Resilient Medical, the valuers had on 28 April 2025 issued the final valuation reports on RMKH Cambodia. Based on the valuation reports commissioned by the Liquidator, the assets of RMKH Cambodia, being primarily equipment, were assessed at a forced liquidation value of approximately US\$782,000. The forced liquidation value represents the valuers' opinion of the gross amount that could typically be realised from a properly advertised and conducted public auction, with the seller being compelled to sell with a sense of immediacy on an "as-is, where-is" basis, as of the valuation date.

On the basis of, *inter alia*, the abovementioned valuation and following the acceptance by the Liquidator of the Company's POD amounting to approximately US\$29.95 million, the Liquidator has on behalf of Resilient Medical declared a dividend *in specie* of Resilient Medical comprising 2,000,000 ordinary shares in the issued share capital of RMKH SG (the "**Distribution**") to the Company, representing 2.61% of the Company's accepted POD. The Liquidator will be taking steps to effect the legal transfer of the entire issued share capital of RMKH SG from Resilient Medical to the Company, and on completion of the Distribution, RMKH SG will be a directly wholly-owned subsidiary of the Company.

As disclosed in the Announcements, RMKH SG, through RMKH Cambodia, is engaged in the manufacturing of nitrile gloves through its nitrile glove factory in Cambodia. Prior to the Distribution and throughout the process of liquidating Resilient Medical, RMKH SG had preserved and enhanced the manufacturing assets and production lines of RMKH Cambodia for manufacturing efficiency, product quality and operational readiness. The Distribution will enable the Company to regain control over RMKH Cambodia, which is now strategically positioned amidst rising global trade uncertainties to meet regional demand for nitrile gloves and other protective personal equipment.

3. FINANCIAL IMPACT

After acquiring equity in RMKH SG, the Company will consolidate both RMKH SG and RMKH Cambodia into the Group's financial statements. Based on our assessment, this consolidation will not have a material impact on the Group's financial position or results.

As at the date of this announcement, the Company is still assessing the impact of the declaration of dividend in specie of shares of RMKH SG on the net tangible assets per share of the Company and the earnings per share of the Company for the current financial year ending 31 December 2025 as further discussions with the Liquidator are necessary to determine the extent of potential recoveries, until the completion of the Distribution.

The Company will make a separate announcement on the completion of the Distribution, as well as any other orders, directions or declarations as may be made by the Liquidator from time to time, at the appropriate juncture.

In the event that there is any further material development on this matter, the Company will make a separate announcement in due course.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 8 May 2025 to the SGX-ST.

*This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").*

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.